Research and Markets: The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth Strategies, Performance

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/1b46ed/the_top_10_compani) has announced the addition of the "The Top 10 Companies in the Hospital Pharmaceutical Market in China: Growth Strategies, Performance and SWOT Analyses" report to their offering.

China is currently the world's second largest economy and could become the world's largest economy sometime as early as 2030. According to IMS Health data, the Chinese hospital pharmaceutical market was valued at around $26bn in 2009. Pharmaceutical companies operating in China comprise both domestic and multinational companies wherein domestic products have over 60% market share. China is one of the emerging markets most targeted by foreign players due to its increasing profitability and access to innovation. This report profiles the leading players in the Chinese hospital pharmaceutical market comprising both domestic and multinational companies. This report analyzes the hospital pharmaceutical market in China in terms of market size, key drivers and resistors, trends, and competitive positioning of major players in the market. It includes profiles of the top 10 companies in the industry and provides a brief summary of other leading players.

Introduction

This report analyzes the hospital pharmaceutical market in China in terms of market size, key drivers and resistors, trends, and competitive positioning of major players in the market. It includes profiles of the top 10 companies in the industry and provides a brief summary of other leading players. rbhc0281

Research and analysis highlights

The hospital pharmaceutical market in China is highly competitive and fragmented, with the top 10 players accounting for 29% of the total sales in 2009. Pfizer captured the highest market share, followed by AstraZeneca and Bayer.

Owing to improving intellectual property rights (IPR), increasing medical insurance coverage of urban and rural residents and growing consumer demand for quality healthcare in China, the Chinese pharmaceutical industry is further expected to grow in the near future.

The hurdles faced by pharmaceutical companies due to the complex drug distribution system and increasing price pressures by the Chinese authorities are resistors to growth of the pharmaceutical industry.

Key Topics Covered:

  • Chapter 1 Scope and methodology
  • Chapter 2 Industry overview
  • Chapter 3 Pfizer
  • Chapter 4 AstraZeneca
  • Chapter 5 Bayer
  • Chapter 6 Sanofi-Aventis
  • Chapter 7 Roche
  • Chapter 8 Js.Yangzijiang Fty
  • Chapter 9 Merck & Co
  • Chapter 10 Kelun group
  • Chapter 11 Shandong Qilu Fty
  • Chapter 12 GlaxoSmithKline (GSK)
  • Chapter 13 11- 15 companies
  • Table of figures
  • Table of tables

For more information visit http://www.researchandmarkets.com/research/1b46ed/the_top_10_compani

Source: Business Insights



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  Asia Pacific  North America  China  New York

INDUSTRY KEYWORDS:   Health  Hospitals  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.